Niagen Bioscience, Inc.
Datakwaliteit: 100%
NAGE
NASDAQ
Manufacturing
Chemicals
€ 4,50
▲
€ 0,02
(0,45%)
Marktkapitalisatie: 359,56 M
Prijs
€ 4,49
Marktkapitalisatie
359,56 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 17,70% annually over 5 years — strong growth
Earnings grew 103,30% over the past year
ROE of 25,78% indicates high profitability
Generating 13,50 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 12,25%
ROIC of 21,51% — excellent capital efficiency
Groei
Revenue Growth (5Y)
17,70%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)29,95%
Earnings (1Y)103,30%
FCF Growth (3Y)37,75%
Kwaliteit
Return on Equity
25,78%
Boven sectorgemiddelde (-53,58%)
ROIC21,51%
Net Margin13,43%
Op. Margin12,58%
Veiligheid
Debt / Equity
N/A
Current Ratio4,12
Interest CoverageN/A
Waardering
PE (TTM|2027)
20,69 | 14,03
Boven sectorgemiddelde (-1,48)
P/B Ratio5,09
EV/EBITDA18,15
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1366 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1366 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 20,7 | -1,5 |
| P/B | 5,1 | 1,6 |
| ROE % | 25,8 | -53,6 |
| Net Margin % | 13,4 | -41,5 |
| Rev Growth 5Y % | 17,7 | 1,8 |
| D/E | — | 0,3 |
Koersdoel Analisten
5 analisten
Buy
Huidig
€ 4,50
Koersdoel
€ 13,60
€ 12,00
€ 13,00
€ 18,00
Vooruitzicht
Forward K/W
14,06
Forward WPA
€ 0,32
WPA Groei (sch.)
+33,3%
Omzet Sch.
171,74 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,32
€ 0,32 – € 0,32
|
171,74 M | 1 |
| FY2026 |
€ 0,24
€ 0,24 – € 0,24
|
147,99 M | 1 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
€ 0,03
€ 0,03 – € 0,03
|
33,23 M | 1 |
| 2026 Q1 |
€ 0,06
€ 0,06 – € 0,06
|
30,36 M | 1 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | € 0,02 | € 0,03 | +65,6% |
| Q32025 | € 0,02 | € 0,05 | +233,3% |
| Q22025 | € 0,01 | € 0,04 | +499,7% |
| Q12025 | € 0,02 | € 0,05 | +172,4% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 29,95% | Revenue Growth (3Y) | 24,45% |
| Earnings Growth (1Y) | 103,30% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 17,70% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 129,42 M | Net Income (TTM) | 17,38 M |
| ROE | 25,78% | ROA | 18,33% |
| Gross Margin | 64,28% | Operating Margin | 12,58% |
| Net Margin | 13,43% | Free Cash Flow (TTM) | 13,50 M |
| ROIC | 21,51% | FCF Growth (3Y) | 37,75% |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4,12 |
| Interest Coverage | N/A | Asset Turnover | 1,36 |
| Working Capital | 70,90 M | Tangible Book Value | 70,43 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 20,69 | Forward P/E | N/A |
| P/B Ratio | 5,09 | P/S Ratio | 2,78 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 18,15 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 3,76% | ||
| Market Cap | 359,56 M | Enterprise Value | 295,46 M |
| Per Share | |||
| EPS (Diluted TTM) | 0,20 | Revenue / Share | 1,62 |
| FCF / Share | 0,17 | OCF / Share | 0,17 |
| EPS CAGR (1Y) | 81,82% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 77,69% |
| SBC-Adj. FCF | 8,45 M | Growth Momentum | 12,25 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 129,42 M | 99,60 M | 83,57 M | 72,05 M | 67,45 M |
| Net Income | 17,38 M | 8,55 M | -4,94 M | -16,54 M | -27,13 M |
| EPS (Diluted) | 0,20 | 0,11 | -0,07 | -0,24 | -0,40 |
| Gross Profit | 83,19 M | 61,59 M | 50,78 M | 42,80 M | 41,49 M |
| Operating Income | 16,28 M | 7,73 M | -5,60 M | -18,63 M | -27,07 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 6,33 M | 6,02 M | 4,96 M | 4,83 M | 3,83 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 661.000,0 | 3.000,0 | 55.000,0 |
| Income Tax | 810.000,0 | 305.000,0 | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 106,41 M | 68,28 M | 54,96 M | 54,06 M | 57,84 M |
| Total Liabilities | 29,87 M | 22,18 M | 26,51 M | 25,39 M | 26,11 M |
| Shareholders' Equity | 76,53 M | 46,09 M | 28,46 M | 28,67 M | 31,73 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | 44,50 M | 27,20 M | 20,30 M | 28,22 M |
| Current Assets | 96,81 M | 64,10 M | 49,53 M | 46,57 M | 48,91 M |
| Current Liabilities | 19,92 M | 17,95 M | 20,62 M | 17,87 M | 17,61 M |
{"event":"ticker_viewed","properties":{"ticker":"NAGE","listing_kind":"stock","pathname":"/stocks/nage","exchange":"NASDAQ","country":"US"}}